233 related articles for article (PubMed ID: 33913699)
1. Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity.
Wang W; Voss KM; Liu J; Gordeev MF
Chem Res Toxicol; 2021 May; 34(5):1348-1354. PubMed ID: 33913699
[TBL] [Abstract][Full Text] [Related]
2. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.
Flanagan S; Bartizal K; Minassian SL; Fang E; Prokocimer P
Antimicrob Agents Chemother; 2013 Jul; 57(7):3060-6. PubMed ID: 23612197
[TBL] [Abstract][Full Text] [Related]
3. Preclinical toxicity evaluation of novel antibacterial contezolid acefosamil in rats and dogs.
Wang W; Li Z; Gordeev MF; Yuan H
J Appl Toxicol; 2024 May; 44(5):770-783. PubMed ID: 38237604
[TBL] [Abstract][Full Text] [Related]
4. In vivo pharmacodynamic study of contezolid acefosamil, a prodrug of contezolid for oral and intravenous administration.
Wang XK; Yu J; Xie CY; Hu XX; Nie TY; Li X; Wang PH; Li GQ; Yuan H; Yang XY; Li CR; You XF
J Antimicrob Chemother; 2023 Jul; 78(7):1632-1636. PubMed ID: 37202829
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of the safety, tolerability, and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects.
Yang H; Jin Y; Wang H; Yuan H; Wang J; Li S; Hu Y; Yang H; Li X; Liang H; Wu J; Cao G; Zhang J
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0079623. PubMed ID: 37902402
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular sympathomimetic amine interactions in rats treated with monoamine oxidase inhibitors and the novel oxazolidinone antibiotic linezolid.
Humphrey SJ; Curry JT; Turman CN; Stryd RP
J Cardiovasc Pharmacol; 2001 May; 37(5):548-63. PubMed ID: 11336106
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic rationale for intravenous contezolid acefosamil followed by oral contezolid dosage regimens.
Bulitta JB; Fang E; Stryjewski ME; Wang W; Atiee GJ; Stark JG; Hafkin B
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0140023. PubMed ID: 38415667
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives.
Phillips OA; D'Silva R; Bahta TO; Sharaf LH; Udo EE; Benov L; Eric Walters D
Eur J Med Chem; 2015 Dec; 106():120-31. PubMed ID: 26536532
[TBL] [Abstract][Full Text] [Related]
9. Advances in contezolid: novel oxazolidinone antibacterial in Gram-positive treatment.
Zhang GX; Liu TT; Ren AX; Liang WX; Yin H; Cai Y
Infection; 2024 Jun; 52(3):787-800. PubMed ID: 38717734
[TBL] [Abstract][Full Text] [Related]
10. Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis.
Wu J; Wu H; Wang Y; Chen Y; Guo B; Cao G; Wu X; Yu J; Wu J; Zhu D; Guo Y; Yuan H; Hu F; Zhang J
Clin Ther; 2019 Jun; 41(6):1164-1174.e4. PubMed ID: 31126694
[TBL] [Abstract][Full Text] [Related]
11. Contezolid in complicated skin and soft tissue infection.
Kaul G; Dasgupta A; Chopra S
Drugs Today (Barc); 2022 Jul; 58(7):315-326. PubMed ID: 35851867
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the monoamine oxidases inhibitory activity of a small series of 5-(azole)methyl oxazolidinones.
Phillips OA; Sharaf LH; D'Silva R; Udo EE; Benov L
Eur J Pharm Sci; 2015 Apr; 71():56-61. PubMed ID: 25701103
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Disposition of Contezolid in Humans: Resolution of a Disproportionate Human Metabolite for Clinical Development.
Wu X; Meng J; Yuan H; Zhong D; Yu J; Cao G; Liu X; Guo B; Chen Y; Li Y; Shi Y; Gordeev MF; Wu J; Zhang J
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0040921. PubMed ID: 34398672
[TBL] [Abstract][Full Text] [Related]
14. A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity
Guo Q; Xu L; Tan F; Zhang Y; Fan J; Wang X; Zhang Z; Li B; Chu H
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0088921. PubMed ID: 34460305
[TBL] [Abstract][Full Text] [Related]
15. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
[TBL] [Abstract][Full Text] [Related]
16. Ranbezolid, a novel oxazolidinone antibacterial: in vivo characterisation of monoamine oxidase inhibitory potential in conscious rats.
Naruganahalli KS; Shirumalla RK; Bansal V; Gupta JB; Das B; Ray A
Eur J Pharmacol; 2006 Sep; 545(2-3):167-72. PubMed ID: 16899241
[TBL] [Abstract][Full Text] [Related]
17. Contezolid: First Approval.
Hoy SM
Drugs; 2021 Sep; 81(13):1587-1591. PubMed ID: 34365606
[TBL] [Abstract][Full Text] [Related]
18. Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine.
Antal EJ; Hendershot PE; Batts DH; Sheu WP; Hopkins NK; Donaldson KM
J Clin Pharmacol; 2001 May; 41(5):552-62. PubMed ID: 11361052
[TBL] [Abstract][Full Text] [Related]
19. Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A.
Reck F; Zhou F; Girardot M; Kern G; Eyermann CJ; Hales NJ; Ramsay RR; Gravestock MB
J Med Chem; 2005 Jan; 48(2):499-506. PubMed ID: 15658863
[TBL] [Abstract][Full Text] [Related]
20. limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30.
Gal S; Abassi ZA; Youdim MB
Neurotox Res; 2010 Aug; 18(2):143-50. PubMed ID: 19894083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
